Quizartinib elicits differential responses that correlate with karyotype and genotype of the leukemic clone.

about

Quizartinib elicits differential responses that correlate with karyotype and genotype of the leukemic clone.

Item

http://www.wikidata.org/entity/Q37052890

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Quizartinib elicits differenti ...... enotype of the leukemic clone.

@en

Quizartinib elicits differenti ...... enotype of the leukemic clone.

@nl

type

Item

label

Quizartinib elicits differenti ...... enotype of the leukemic clone.

@en

Quizartinib elicits differenti ...... enotype of the leukemic clone.

@nl

prefLabel

Quizartinib elicits differenti ...... enotype of the leukemic clone.

@en

Quizartinib elicits differenti ...... enotype of the leukemic clone.

@nl

P1476

Quizartinib elicits differenti ...... enotype of the leukemic clone.

@en

P2093

A Bagg

http://www.w3.org/2001/XMLSchema#string

A E Perl

http://www.w3.org/2001/XMLSchema#string

C C Smith

http://www.w3.org/2001/XMLSchema#string

C D Watt

http://www.w3.org/2001/XMLSchema#string

D Roy

http://www.w3.org/2001/XMLSchema#string

G E Nybakken

http://www.w3.org/2001/XMLSchema#string

J Canaani

http://www.w3.org/2001/XMLSchema#string

J D Morrissette

http://www.w3.org/2001/XMLSchema#string

M Carroll

http://www.w3.org/2001/XMLSchema#string

N P Shah

http://www.w3.org/2001/XMLSchema#string

P2860

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

Role of nucleophosmin in embryonic development and tumorigenesis

Dnmt3a is essential for hematopoietic stem cell differentiation.

Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia.

DNMT3A Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous Leukemia

Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML.

Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications.

Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways.

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

P2888

leu.2015.320

P304

1422-1425

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2015.320

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-11-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26585411

http://www.w3.org/2001/XMLSchema#string

P921

karyotype

leukemia

P932

4927337

http://www.w3.org/2001/XMLSchema#string